While it is well documented that cytokines play an important role in anti-cancer immunity, our data provide the underlying explanation for failure of agents targeting PI3K pathway in clinical trials and a rationale for the combined treatment with PI3K/Akt/mTOR inhibitors and immunological therapy. This evidence concerns the gene MTOR and cancer.